ライフサイエンスコーパス: hemoperfusion

1 57) after excluding trials using polymyxin B hemoperfusion.

2 tients both before and at various times post-hemoperfusion.

3 or post-transplantation using extracorporeal hemoperfusion.

4 eptic shock and terms related to polymyxin B hemoperfusion.

5 Hemoperfusion and on-line removal of superantigens merit

6 A lower index of retinal hemoperfusion density and a high level of VEGF-A were no

7 Retinal hemoperfusion density and VEGF-A concentration were expe

8 Evaluation of retinal hemoperfusion density and VEGF-A levels in tears are inf

9 lar edema, characterized by a higher retinal hemoperfusion density in the foveal and the parafoveal z

10 l examination included measuring the macular hemoperfusion density.

11 inly influenced by studies using polymyxin B hemoperfusion from Japan.

12 nt time, endotoxin removal through cartridge hemoperfusion is one of the better alternatives to comba

13 uggests that plasma exchange and polymyxin-B hemoperfusion may provide potential benefits for adult p

14 oal (AC), which is commonly used in clinical hemoperfusion of aqueous toxins, in terms of Gd capture

15 dies investigating the effect of polymyxin B hemoperfusion on mortality were considered eligible.

16 81 (95% CI, 0.70-0.95), favoring polymyxin B hemoperfusion (p = 0.007).

17 Blood purification techniques including hemoperfusion, plasma exchange, and hemofiltration with

18 Polymyxin-B hemoperfusion (relative risk [RR]: 0.70; 95% CI, 0.57-0.

19 tivity, the potential benefit of polymyxin-B hemoperfusion remained inconclusive.

20 The therapeutic effect of polymyxin-B hemoperfusion remains uncertain.

21 However, these results were driven mainly by hemoperfusion (risk ratio, 0.63 [95% CI, 0.50-0.80]; p<0

22 facilitates whole body removal of Gd using a hemoperfusion system consisting of a cartridge of porous

23 In the CKD rat model, the 1,2-HOPO-Davisil hemoperfusion system removed Gd by 3.4 times over the Ga

24 Herein, we report optimization of the hemoperfusion system using an ex vivo blood and an in vi

25 rough a alphaGal6 immunoaffinity column with hemoperfusion through a pig liver for changes in blood p

26 Hemodialysis, hemoperfusion, thymidine, and carboxypeptidase have been

27 reported a survival benefit for polymyxin B hemoperfusion treatment in patients with severe sepsis a

28 present study demonstrated that polymyxin B hemoperfusion treatment may reduce mortality in patients

29 lysis to determine the effect of polymyxin B hemoperfusion treatment on mortality in patients with se

30 reported no survival benefit for polymyxin B hemoperfusion treatment.

31 asmapheresis, thalidomide, cyclophosphamide, hemoperfusion, tumor necrosis factor inhibitors, and gra

32 blood purification therapy comprising direct hemoperfusion using a polymyxin B-immobilized fiber colu

33 on, plasma exchange, and hemofiltration with hemoperfusion were associated with lower mortality in pa

34 of AFB(1) (0.5-1.0 mg/kg) intravenously and hemoperfusion with a CS or Control device was initiated